Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | MITF | O75030 | 1/20 | 0.34 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylglyoxal SCHEMBL8854695 | 0.86 | PTPN1 (0.41) | CA1CA2CA9ALDH1A1KDM4E | |
| Methylglyoxal SCHEMBL6452706 | 0.75 | CTSD (0.38) | CTSDMEN1KMT2ACA1CA2 | |
| SCHEMBL961664 | 0.75 | CTSD (0.50) | CTSDMEN1KMT2ACA1CA2 | |
| Methylglyoxal SCHEMBL2950078 | 0.73 | CTSD (0.49) | CTSDMEN1KMT2ACA1CA2 | |
| Methylglyoxal SCHEMBL3950700 | 0.73 | CTSD (0.40) | CTSDMEN1KMT2ACA1CA2 | |
| Methylglyoxal SCHEMBL8854728 | 0.72 | CTSD (0.47) | CTSDMEN1KMT2ACA1CA2 | |
| SCHEMBL962276 | 0.71 | ALDH1A1 (0.62) | CTSDMEN1KMT2ACA1CA2 | |
| SCHEMBL959111 | 0.69 | CTSD (0.47) | CTSDMEN1KMT2ACA1CA2 | |
| SCHEMBL959908 | 0.68 | CTSD (0.50) | CTSDMEN1KMT2ACA1CA2 | |
| SCHEMBL10921933 | 0.68 | CTSD (0.49) | CTSDMEN1KMT2ACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070065443-A1 | Fructoseamine 3 kinase and the formation of collagen and elastin | DYNAMIS THERAPEUTICS, INC. | 2007-03-22 | — | — | US | claimed |
| US-20050159383-A1 | Administering enzyme inhibitors; wrinkling and aging resistance; prevents formation Advanced Glycation End Products (AGEs) | DYNAMIS THERAPEUTICS, INC. | 2005-07-21 | — | — | US | claimed |
| US-20030219440-A1 | 3-deoxyglucosone and skin | DYNAMIS THERAPEUTICS, INC. | 2003-11-27 | — | — | US | claimed |
| US-5661139-A | FOR INHIBITING GLYCOSYLATION OF PROTEINS TO PREVENT DISCOLORATION OF THE TEETH | ALTEON INC. (US) | 1997-08-26 | — | — | US | claimed |
| WO-1996040622-A1 | BIS-(2-ARYL)HYDRAZONES AS INHIBITORS OF THE FORMATION OF ADVANCED GLYCOSYLATION ENDPRODUCTS | ALTEON INC. (US) | 1996-12-19 | — | — | WO | claimed |
| US-20100310482-A1 | 3-Deoxyglucosone And Skin | DYNAMIS THERAPEUTICS, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-7749503-B2 | 3-deoxyglucosone and skin | DYNAMIS THERAPEUTICS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-7671019-B2 | Administering enzyme inhibitors; wrinkling and aging resistance; prevents formation Advanced Glycation End Products (AGEs) | DYNAMIS THERAPEUTICS, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7622117-B2 | 3-deoxyglucosone and skin | DYNAMIS THERAPEUTICS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20080292568-A1 | 3-Deoxyglucosone and skin | DYNAMIS THERAPEUTICS, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-20070065443-A1 | Fructoseamine 3 kinase and the formation of collagen and elastin | DYNAMIS THERAPEUTICS, INC. | 2007-03-22 | — | — | US | disclosed |
| US-20060089316-A1 | Method for reducing a susceptibility to tumor formation induced by 3-deoxyglucosone and precursors thereof | BROWN TRUMAN R | 2006-04-27 | — | — | US | disclosed |
| US-20050159383-A1 | Administering enzyme inhibitors; wrinkling and aging resistance; prevents formation Advanced Glycation End Products (AGEs) | DYNAMIS THERAPEUTICS, INC. | 2005-07-21 | — | — | US | disclosed |
| US-20030219440-A1 | 3-deoxyglucosone and skin | DYNAMIS THERAPEUTICS, INC. | 2003-11-27 | — | — | US | disclosed |
| US-5661139-A | FOR INHIBITING GLYCOSYLATION OF PROTEINS TO PREVENT DISCOLORATION OF THE TEETH | ALTEON INC. (US) | 1997-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070065443-A1 | Fructoseamine 3 kinase and the formation of collagen and elastin | FN3K, PDXK, COLGALT1 | CTSD 1950/4885MEN1 1069/4885KMT2A 2468/4885 |
| US-20060089316-A1 | Method for reducing a susceptibility to tumor formation induced by 3-deoxyglucosone and precursors thereof | ALDOA, FBP1, GYS2 | CTSD 3411/4885MEN1 1158/4885KMT2A 2155/4885 |
| US-20100310482-A1 | 3-Deoxyglucosone And Skin | DPM1, G6PD, UGGT1 | CTSD 2092/4885MEN1 1559/4885KMT2A 3495/4885 |
| US-20080292568-A1 | 3-Deoxyglucosone and skin | DPM1, G6PD, UGGT1 | CTSD 2092/4885MEN1 1559/4885KMT2A 3495/4885 |
| US-20030219440-A1 | 3-deoxyglucosone and skin | DPM1, G6PD, UGGT1 | CTSD 2092/4885MEN1 1559/4885KMT2A 3495/4885 |
| US-20050159383-A1 | Administering enzyme inhibitors; wrinkling and aging resistance; prevents formation Advanced Glycation End Products (AGEs) | AGER, GLA, GALE | CTSD 428/4885MEN1 3627/4885KMT2A 2646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.